Extracellular Vesicle PD-L1 Detection for Cancer Therapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune checkpoint blockade therapies for cancer, such as those targeting the PD-L1/PD-1 axis, have limited efficacy and predictability, with only a minority of patients responding effectively, and there is a need for better molecular understanding of tumor-immune system interactions to improve treatment outcomes.
Innovation Solution
The method involves detecting and monitoring levels of circulating extracellular vesicle PD-L1 and interferon γ (IFNγ) in biological samples before and after treatment to identify responsive patients and using specific reagents to bind and deplete PD-L1 from the blood, thereby inhibiting cancer metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint blockade therapies targeting PD-L1/PD-1 axis are used, then immune response is enhanced, but treatment efficacy and predictability remain limited
Solution Approach 1:
The patent applies preliminary action by measuring extracellular vesicle PD-L1 levels in biological samples before administering immune checkpoint blockade therapy. This pre-treatment measurement allows clinicians to predict which patients are most likely to respond to therapy, enabling informed treatment decisions before therapy begins. The method identifies responsive patients in advance, thereby improving treatment efficacy and reducing response variability.
Solution Approach 2:
The patent implements feedback by monitoring changes in extracellular vesicle PD-L1 levels before and after treatment. By comparing pre-treatment and post-treatment samples, the method provides feedback on treatment response, allowing clinicians to assess whether the therapy is working and make adjustments if necessary. This feedback mechanism enhances both treatment efficacy and predictability.
2Productivity
If only a minority of patients are identified as responders, then treatment resources are concentrated on effective cases, but most patients do not benefit from therapy
Solution Approach 1:
By measuring extracellular vesicle PD-L1 levels before treatment, the patent enables preliminary identification of patients who are most likely to respond to immune checkpoint blockade therapy. This pre-screening approach allows clinicians to prioritize treatment for responsive patients, potentially improving overall treatment success rates by avoiding ineffective treatments in non-responders.
Solution Approach 2:
The patent utilizes parameter changes by monitoring the dynamic levels of extracellular vesicle PD-L1 before and after treatment. This quantitative measurement approach transforms the assessment from qualitative clinical observation to quantitative biomarker analysis, enabling more precise identification of treatment responders and non-responders.
3Object-affected harmful factors
If PD-L1 on cancer cell surface is targeted, then local immune inactivation occurs, but systemic immune monitoring and prediction capability is insufficient
Solution Approach 1:
The patent introduces extracellular vesicles as intermediaries to bridge the gap between local tumor immunity and systemic immune monitoring. These vesicles carry PD-L1 and can be detected in circulating blood, serving as a mediator that provides systemic information about tumor-immune interactions. This intermediary approach allows non-invasive monitoring of immune response dynamics throughout the body.
Solution Approach 2:
The patent replaces direct mechanical observation of tumor-cell PD-L1 expression with a biochemical detection system that measures extracellular vesicle PD-L1 levels in blood samples. This substitution transforms the assessment from localized tissue analysis to systemic biochemical monitoring, enabling remote and repeated measurement of immune response status.
Data Source
AI summary
Compositions and methods are disclosed for treating cancer patients and identifying patients with a malignancy that are likely to respond to treatment with anti-PD-1/PD-L1 and other anti-cancer and immune-modulating therapeutics.